ABL1 and acute promyelocytic leukemia: The most well-known therapies are all-trans retinoic acid (ATRA) for treating acute promyelocytic leukemia (APL) and imatinib mesylate (Gleevec) that targets a BCR-ABL oncogene in chronic myeloid leukemia (CML) [6,7].